Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as we… Read more
Equillium Inc (EQ) - Total Assets
Latest total assets as of September 2025: $34.51 Million USD
Based on the latest financial reports, Equillium Inc (EQ) holds total assets worth $34.51 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Equillium Inc - Total Assets Trend (2017–2024)
This chart illustrates how Equillium Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Equillium Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Equillium Inc's total assets of $34.51 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.6% |
| Accounts Receivable | $1.14 Million | 4.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Equillium Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Equillium Inc's current assets represent 97.6% of total assets in 2024, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 70.6% of total assets in 2024, down from 99.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
Equillium Inc Competitors by Total Assets
Key competitors of Equillium Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Equillium Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Equillium Inc generates 1.61x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Equillium Inc is currently not profitable relative to its asset base.
Equillium Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.85 | 3.04 | 11.79 |
| Quick Ratio | 10.85 | 3.04 | 11.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $30.48 Million | $ 22.59 Million | $ 78.18 Million |
Equillium Inc - Advanced Valuation Insights
This section examines the relationship between Equillium Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.92 |
| Latest Market Cap to Assets Ratio | 2.44 |
| Asset Growth Rate (YoY) | -49.3% |
| Total Assets | $25.60 Million |
| Market Capitalization | $62.43 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Equillium Inc's assets at a significant premium ( 2.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Equillium Inc's assets decreased by 49.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Equillium Inc (2017–2024)
The table below shows the annual total assets of Equillium Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $25.60 Million | -49.33% |
| 2023-12-31 | $50.53 Million | -35.57% |
| 2022-12-31 | $78.42 Million | -8.18% |
| 2021-12-31 | $85.41 Million | -0.03% |
| 2020-12-31 | $85.43 Million | +53.82% |
| 2019-12-31 | $55.54 Million | -17.31% |
| 2018-12-31 | $67.16 Million | +839.15% |
| 2017-12-31 | $7.15 Million | -- |